Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 8/20 | 0.62 |
| ▸ | ACHE | P22303 | 8/20 | 0.62 |
| ▸ | BCHE | P06276 | 6/20 | 0.62 |
| ▸ | TYR | P14679 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.44 |
| ▸ | ALDH1A3 | P47895 | 2/20 | 0.44 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.44 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2047680 | 0.91 | PTGS2 (0.53) | PTGS2ACHEBCHETYRNPC1 | |
| SCHEMBL9879225 | 0.90 | PTGS2 (0.56) | PTGS2ACHEBCHETYRNPC1 | |
| SCHEMBL6394314 | 0.82 | PTGS2 (0.57) | PTGS2ACHEBCHENPC1RAB9A | |
| SCHEMBL9944620 | 0.82 | TYR (0.55) | PTGS2ACHEBCHETYRALDH1A1 | |
| SCHEMBL6286470 | 0.81 | TYR (0.48) | PTGS2ACHEBCHETYRALDH1A1 | |
| SCHEMBL15145397 | 0.80 | PTGS2 (0.57) | PTGS2ACHEBCHENPC1RAB9A | |
| SCHEMBL6141293 | 0.78 | ACHE (0.51) | PTGS2ACHEBCHENPC1RAB9A | |
| SCHEMBL19984540 | 0.78 | PTGS2 (0.65) | PTGS2ACHEBCHETYRNPC1 | |
| SCHEMBL2048449 | 0.78 | PTGS2 (0.44) | PTGS2ACHEBCHENPC1RAB9A | |
| SCHEMBL28952511 | 0.77 | PTGS2 (0.54) | PTGS2ACHEBCHENPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 594 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110156734-B | Fluorescent probe and fluorescent test paper for detecting nerve gas simulant and preparation method thereof | 深圳大学 | 2020-08-18 | — | — | CN | claimed |
| CN-110156734-A | A kind of fluorescence probe, fluorescent test paper and preparation method thereof for simulating analyte detection for nerve gas | 深圳大学 | 2019-08-23 | — | — | CN | claimed |
| US-20100022769-A1 | NOVEL POLYNITROGENATED SYSTEMS AS ANTI-HIV AGENTS | INSTITUT QUIMIC DE SARRIA CETS (ES) | 2010-01-28 | — | — | US | claimed |
| EP-2100890-A1 | NOVEL POLYNITROGENATED SYSTEMS AS ANTI-HIV AGENTS | Institut Quimic De Sarria Cets (ES) | 2009-09-16 | — | — | EP | claimed |
| CN-122011416-A | Organosilicon supermolecular elastomer based on crown ether host-guest effect crosslinking and preparation method thereof | 山东大学 | 2026-05-12 | — | — | CN | disclosed |
| CN-116217566-B | Anti-apoptosis protein BCL-2 inhibitor, pharmaceutical composition and application thereof | 杭州和正医药有限公司 | 2025-05-23 | — | — | CN | disclosed |
| CN-119735563-A | Thiazolidinones as NLRP3 protein inhibitors | 润药仁智(北京)科技有限公司 | 2025-04-01 | — | — | CN | disclosed |
| US-20250034135-A1 | ANTI-APOPTOTIC PROTEIN BCL-2 INHIBITOR, PHARMACEUTICAL COMPOSITION AND USES THEREOF | Hangzhou Healzen Therapeutics Co., Ltd. (CN) | 2025-01-30 | — | — | US | disclosed |
| US-20250026742-A1 | COMPOUND AS ATR KINASE INHIBITOR | SUZHOU ARK BIOPHARMACEUTICAL CO., LTD. (CN) | 2025-01-23 | — | — | US | disclosed |
| EP-4442685-A1 | ANTI-APOPTOTIC PROTEIN BCL-2 INHIBITOR, PHARMACEUTICAL COMPOSITION AND USES THEREOF | Hangzhou HealZen Therapeutics Co., Ltd. (CN) | 2024-10-09 | — | — | EP | disclosed |
| EP-4382611-A1 | SENSORS FOR 3-HYDROXYBUTYRATE DETECTION | Medtronic MiniMed, Inc. (US) | 2024-06-12 | — | — | EP | disclosed |
| US-20240065585-A1 | SENSORS FOR 3-HYDROXYBUTYRATE DETECTION | MEDTRONIC MINIMED, INC. (US) | 2024-02-29 | — | — | US | disclosed |
| US-5036079-A | Anticholesterol | PFIZER INC. (US) | 1991-07-30 | — | — | US | disclosed |
| WO-1991009849-A1 | DIAROMATIC SUBSTITUTED ANTI-AIDS COMPOUNDS | THE UPJOHN COMPANY (US) | 1991-07-11 | — | — | WO | disclosed |
| CN-1036572-A | Thiazolidinedione derivatives for lowering blood glucose | PFIZER (US) | 1989-10-25 | — | — | CN | disclosed |
| WO-1989008650-A1 | THIAZOLIDINEDIONE HYPOGLYCEMIC AGENTS | PFIZER INC. (US) | 1989-09-21 | — | — | WO | disclosed |
| EP-0332332-A1 | Hypoglycemic thiazolidinedione derivatives | PFIZER INC. (US) | 1989-09-13 | — | — | EP | disclosed |
| EP-0332331-A2 | Thiazolidinedione hypoglycemic agents | PFIZER INC. (US) | 1989-09-13 | — | — | EP | disclosed |
| US-4528114-A | Acetylenes | HOFFMANN-LA ROCHE INC. (US) | 1985-07-09 | — | — | US | disclosed |
| US-4350833-A | REACTING TEREPHTHALALDEHYDE WITH AN ALCOHOL IN PRESENCE OF ACID CATALYSTS | AGENCY OF INDUSTRIAL SCIENCE & TECHNOLOGY, MINISTRY OF INTERNATIONAL TRADE & INDUSTRY (JP) | 1982-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250026742-A1 | COMPOUND AS ATR KINASE INHIBITOR | ATR, CHEK2, CHEK1 | PTGS2 4403/4885ACHE 3859/4885BCHE 3043/4885 |
| US-20100022769-A1 | NOVEL POLYNITROGENATED SYSTEMS AS ANTI-HIV AGENTS | MSR1, CCR5, CD4 | PTGS2 1051/4885ACHE 3563/4885BCHE 1130/4885 |
| US-20250034135-A1 | ANTI-APOPTOTIC PROTEIN BCL-2 INHIBITOR, PHARMACEUTICAL COMPOSITION AND USES THEREOF | BCL2, BAX, BCL2L1 | PTGS2 222/4885ACHE 4201/4885BCHE 2901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.